Navigation Links
Combo Therapy Helps Multiple Myeloma Patients

Three-quarters of those who had relapsed saw disease stabilize or improve, study shows

FRIDAY, Dec. 12 (HealthDay News) -- A new combination of medicines designed to boost immune function can help some multiple myeloma patients, according to interim results from an ongoing Mayo Clinic study.

The researchers found that combining a new immunomodulatory drug called pomalidomide with dexamethasone (pom/dex) improved or stabilized disease in 76 percent of multiple myeloma patients who'd relapsed after previous treatment.

Multiple myeloma, a cancer that begins in white blood cells called plasma cells, affects about three in 100,000 people per year. There is no cure, but the disease can be managed. Immunomodulatory drugs interfere with cancer cell growth and stimulate the immune system to attack cancer cells.

The Mayo study began in November 2007 and has enrolled 60 patients, who took 2 milligrams of pomalidomide orally a day for a 28-day cycle and 40 mg of dexamethasone orally on days 1, 8, 15 and 22. They also took 325 mg of aspirin daily to prevent blood clots, a potential problem for patients taking immunomodulatory drugs.

Of the 60 patients, 58 percent have responded to therapy with at least a 50 percent decrease in detectable tumor burden as measured by blood protein levels, a marker for myeloma. This includes one patient who achieved complete remission, 14 patients who achieved at least a 90 percent decrease in blood proteins and 11 patients who remained stable.

"These are high remission rates, and they happened quickly," lead researcher and hematologist Dr. Martha Lacy said in a Mayo news release.

Side effects included anemia and declines in blood counts. In most patients, these side effects were mild.

Pomalidomide, also called CC-4047, belongs to the same class of immunomodulatory drugs as thalidomide and lenalidomide, both of which have been approved by the U.S. Food and Drug Administration for use with dexamethasone for multiple myeloma patients who've had previous treatment.

The Mayo researchers found that pom/dex was helpful in 29 percent of patients who didn't respond to lenalidomide.

The interim results of the study, funded by Celgene, were presented at the annual meeting of the American Society of Hematology.

"We are excited about the potential of this drug combination to significantly help patients with myeloma. Based on these encouraging results, we are expanding the study to include other patient populations that may benefit from this therapy," Lacy said.

More information

The American Cancer Society has more about multiple myeloma.

-- Robert Preidt

Mayo Clinic, news release, Dec. 9, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Blood Pressure Pill Combo More Effective Than Diuretics
2. U.S. Cancer Rate-Death Rate Combo Drops for 1st Time
3. Combo Treatment Best for Anxiety Disorder in Kids
4. Vaginal/Caesarean combo delivery of twins safe, UT Southwestern-led research finds
5. Drug/radiation combo may help shrink established tumors
6. Inverness Medical Innovations Announces 4th Generation Rapid HIV Test - Determine(TM) HIV-1/2 Ag/Ab Combo
7. Once-Daily Combo Works for New HIV Patients
8. Two-Drug Combo Reduces Diabetic Kidney Damage
9. 3-Drug Combo Improves Advanced Pancreatic Cancer Outcomes
10. Combo Therapy Knocks Out Melanoma Tumors
11. Combo Kidney-Pancreas Transplant Boosts Survival in Diabetics
Post Your Comments:
Related Image:
Combo Therapy Helps Multiple Myeloma Patients
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: